Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty
Purpose This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche. Methods We retrospectively reviewed medical records of 39 fem...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Pediatric Endocrinology
2021-09-01
|
| Series: | Annals of Pediatric Endocrinology & Metabolism |
| Subjects: | |
| Online Access: | http://e-apem.org/upload/pdf/apem-2040220-110.pdf |
| _version_ | 1819282274719367168 |
|---|---|
| author | Vickie Wu Victoria Zhao Rula Issa Meredith Wilkes Elizabeth Wallach Robert Rapaport Christopher Romero Mabel Yau |
| author_facet | Vickie Wu Victoria Zhao Rula Issa Meredith Wilkes Elizabeth Wallach Robert Rapaport Christopher Romero Mabel Yau |
| author_sort | Vickie Wu |
| collection | DOAJ |
| description | Purpose This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche. Methods We retrospectively reviewed medical records of 39 females with CPP who reached menarche after GnRHa treatment (leuprolide or histrelin). CPP diagnostic criteria were breast development at <8 years old, measurable pubertal luteinizing hormone and/or estradiol concentrations, and bone age advancement. Indications to treat were advanced bone age and psychosocial concerns. Descriptive summaries were reported as frequency and proportion for categorical variables and mean and standard deviation for continuous measures. Linear regression models were developed to evaluate the associations of clinical factors with the time interval to menarche. Results Mean age was 9.4±1.6 years at treatment onset, and treatment duration was 2.2±1.4 years. Menarche occurred at 12.6±1.1 years, which was 1.04±0.5 years after treatment discontinuation. This was negatively associated with Tanner stage of breast development and bone age at treatment onset and change in bone age during treatment. No association was seen between time interval to menarche and treatment duration, medication, or body mass index. Conclusions We found the average time interval to menarche after GnRHa treatment in our population of female patients with CPP to be 1.04±0.5 years; this is in agreement with other reports. Tanner stage of breast development, bone age at treatment onset, and change in bone age were negatively associated with time interval to menarche. These data provide clinical correlates that assist providers during anticipatory guidance of patients with CPP after GnRHa treatment. |
| first_indexed | 2024-12-24T01:12:59Z |
| format | Article |
| id | doaj.art-645da12cb16b4bf292fd6d2520e46e8a |
| institution | Directory Open Access Journal |
| issn | 2287-1012 2287-1292 |
| language | English |
| last_indexed | 2024-12-24T01:12:59Z |
| publishDate | 2021-09-01 |
| publisher | Korean Society of Pediatric Endocrinology |
| record_format | Article |
| series | Annals of Pediatric Endocrinology & Metabolism |
| spelling | doaj.art-645da12cb16b4bf292fd6d2520e46e8a2022-12-21T17:22:51ZengKorean Society of Pediatric EndocrinologyAnnals of Pediatric Endocrinology & Metabolism2287-10122287-12922021-09-0126318519110.6065/apem.2040220.110869Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious pubertyVickie Wu0Victoria Zhao1Rula Issa2Meredith Wilkes3Elizabeth Wallach4Robert Rapaport5Christopher Romero6Mabel Yau7 Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Pediatric Endocrinology, Icahn School of Medicine at Mount Sinai, New York, NY, USAPurpose This study aimed to evaluate the time interval to menarche after gonadotropin-releasing hormone agonist (GnRHa) treatment in females with central precocious puberty (CPP) and to identify factors contributing to timing of menarche. Methods We retrospectively reviewed medical records of 39 females with CPP who reached menarche after GnRHa treatment (leuprolide or histrelin). CPP diagnostic criteria were breast development at <8 years old, measurable pubertal luteinizing hormone and/or estradiol concentrations, and bone age advancement. Indications to treat were advanced bone age and psychosocial concerns. Descriptive summaries were reported as frequency and proportion for categorical variables and mean and standard deviation for continuous measures. Linear regression models were developed to evaluate the associations of clinical factors with the time interval to menarche. Results Mean age was 9.4±1.6 years at treatment onset, and treatment duration was 2.2±1.4 years. Menarche occurred at 12.6±1.1 years, which was 1.04±0.5 years after treatment discontinuation. This was negatively associated with Tanner stage of breast development and bone age at treatment onset and change in bone age during treatment. No association was seen between time interval to menarche and treatment duration, medication, or body mass index. Conclusions We found the average time interval to menarche after GnRHa treatment in our population of female patients with CPP to be 1.04±0.5 years; this is in agreement with other reports. Tanner stage of breast development, bone age at treatment onset, and change in bone age were negatively associated with time interval to menarche. These data provide clinical correlates that assist providers during anticipatory guidance of patients with CPP after GnRHa treatment.http://e-apem.org/upload/pdf/apem-2040220-110.pdfprecocious pubertygonadotropin-releasing hormonemenarche |
| spellingShingle | Vickie Wu Victoria Zhao Rula Issa Meredith Wilkes Elizabeth Wallach Robert Rapaport Christopher Romero Mabel Yau Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty Annals of Pediatric Endocrinology & Metabolism precocious puberty gonadotropin-releasing hormone menarche |
| title | Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty |
| title_full | Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty |
| title_fullStr | Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty |
| title_full_unstemmed | Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty |
| title_short | Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty |
| title_sort | clinical findings influencing time to menarche post gonadotropin releasing hormone agonist therapy in central precocious puberty |
| topic | precocious puberty gonadotropin-releasing hormone menarche |
| url | http://e-apem.org/upload/pdf/apem-2040220-110.pdf |
| work_keys_str_mv | AT vickiewu clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT victoriazhao clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT rulaissa clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT meredithwilkes clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT elizabethwallach clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT robertrapaport clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT christopherromero clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty AT mabelyau clinicalfindingsinfluencingtimetomenarchepostgonadotropinreleasinghormoneagonisttherapyincentralprecociouspuberty |